Press Releases

Partnerships

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. T...

bioMérieux – Third-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths fr...

bioMérieux – First-Half 2021 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 31 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statemen...

bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants

bioMérieux, a world leader in the field of in vitro diagnostics, has launched EPISEQ® SARS-COV-2, a genomic software solution to support microbiology labs in identification and reporting from raw sequ...

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

Marcy l’Étoile, France and Mountain View, California – bioMérieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems ...